(Q41740650)

8 October 2017

Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates (English)

1 reference

8 October 2017

2

B D Cheson

1 reference

8 October 2017

A J Grillo-López

1

1 reference

8 October 2017

S J Horning

3

1 reference

8 October 2017

B A Peterson

4

1 reference

8 October 2017

W D Carter

5

1 reference

8 October 2017

C L Varns

6

1 reference

8 October 2017

D L Klippenstein

7

1 reference

8 October 2017

C D Shen

8

1 reference

8 October 2017

language of work or name

1 reference

1 April 2000

1 reference

8 October 2017

1 reference

8 October 2017

11

1 reference

8 October 2017

4

1 reference

8 October 2017

399-408

1 reference

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting

8 October 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Results of MIME salvage regimen for recurrent or refractory lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Fludarabine phosphate for the treatment of low grade lymphoid malignancy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

2-Chlorodeoxyadenosine treatment of low-grade lymphomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with a high-dose doxorubicin-containing regimen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Analysis of interobserver and intraobserver variability in CT tumor measurements

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

A randomized comparison of methotrexate dose and the addition of bleomycin to chop therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas cancer and leukemia group B study 7851

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Clinical significance of morphologic subdivision in diffuse large cell lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332713631

7 January 2021

Identifiers

DOI

10.1023/A:1008332713631

1 reference

8 October 2017

1 reference